Please login to the form below

Not currently logged in
Email:
Password:

Drug prices

This page shows the latest Drug prices news and features for those working in and with pharma, biotech and healthcare.

Not in my backyard

Not in my backyard

And if 40% of US prescriptions flow through Canada, the branded prescription drug supply would dry up in less than six months. ... I think we’re all for lowering drug prices. And I know we’re all for helping patients access affordable medicine.

Latest news

  • Mylan gets first biosimilar Herceptin OK from FDA Mylan gets first biosimilar Herceptin OK from FDA

    have suggested it will start making revenues from the drug in 2019 – the year in which Roche’s US patent on Herceptin expires. ... This is the eighth biosimilar approved by the FDA in quick succession as the agency tries to take action on high drug

  • AZ prices severe asthma drug Fasenra below competition AZ prices severe asthma drug Fasenra below competition

    AZ prices severe asthma drug Fasenra below competition. The discounted drug will cost $38, 000 in the first year. ... The drug is also on the brink of EU approval having picked up a CHMP positive opinion late last week.

  • Merck CEO resigns from Trump post in Charlottesville protest Merck CEO resigns from Trump post in Charlottesville protest

    more time to LOWER RIPOFF DRUG PRICES!" Merck has not however been among pharma companies singled out for price hikes, and has in fact been very transparent about its pricing strategy. ... The spat comes as the Trump administration is reportedly in the

  • The quietest problem in healthcare is a palindrome The quietest problem in healthcare is a palindrome

    The tenor of our discussion in healthcare tends to focus on drug prices, doctors’salaries, insurance companies, pharmacy benefits managers, adverse events, regulatory issues, patent laws and special vouchers for breakthrough ... The prices of drugs are

  • US scientists still wary of Gottlieb's industry ties US scientists still wary of Gottlieb's industry ties

    that Gottlieb would lead the FDA in the interest of the public to help lower drug prices. ... On the latter point, 37% of respondents overall said the pharma industry was most responsible for high drug prices although interestingly - and unsurprisingly -

More from news
Approximately 4 fully matching, plus 146 partially matching documents found.

Latest Intelligence

  • Health on instalment Health on instalment

    For example, the ophthalmic drug Luxturna, approved last year, costs $850, 000 per dose. ... In a company statement, even chief medical officer of pharmacy benefit manager Express Scripts Steve Miller, usually a fierce critic of high drug prices, offered

  • The rise of real-world evidence The rise of real-world evidence

    Notably, manufacturers and government and private payers are responding to concerns about drug prices by tying payments to outcomes. ... Spark Therapeutics has a similar arrangement for its gene therapy. These agreements make real-world efficacy a

  • US health reforms US health reforms

    In fact, it’s safe to say most C-suite drug executives would hardly shed a tear upon news of Obamacare’s swift demise. ... added. President Trump himself has frequently called for lower drug prices. “Once healthcare reform is done and Obamacare has

  • A healthcare landscape going through seismic change A healthcare landscape going through seismic change

    insulation from the looming challenges which now include Brexit and drug pricing in the UK. ... The company is still reeling from its record £84.2m fine last December from the UK government’s Competition and Markets Authority for allegedly charging

  • Managing medication non-adherence Managing medication non-adherence

    Recouping that cost by attempting to raise drug prices is not an option in the current climate but optimising adherence outcomes to accomplish the same goal achieves revenue, drug efficacy and ... Tasked with building out digital service capabilities to

More from intelligence
Approximately 2 fully matching, plus 17 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • A roadmap to strategic drug pricing

    A roadmap to strategic drug pricing. The current unit-based pricing model for drugs is too one-dimensional for the market's present needs. ... A roadmap to strategic drug pricing.

  • Oncology drugs under AMNOG

    Oncology drugs under AMNOG. Part 1: Segmentation and comparator choice - lessons for cancer drug market access in Germany. ... How to prepare. Germany is one of the largest pharmaceutical markets in Europe and drug prices there are used as reference

  • Oncology drugs under AMNOG

    Oncology drugs under AMNOG. Part 1: Segmentation and comparator choice - lessons for cancer drug market access in Germany. ... How to prepare. Germany is one of the largest pharmaceutical markets in Europe and drug prices there are used as reference

More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics